Biotech Showcase™ Celebrates Record Attendance by Life Science Investors, CEOs

Biotech
Showcase™, one of the most influential international biotechnology
investor conferences in the world, concluded in San Francisco the second
week of January and brought together more than 3,600 decision makers and
biotech investors shaping the biopharmaceutical industry. This year’s
event marks the largest number of investors and overall attendees in the
eleven-year history of the conference. Biotech Showcase is produced
jointly by Demy-Colton and EBD
Group.

“During healthcare’s busiest week of the year, we are proud to be the
leading platform for small- and mid-cap public and private biotech
companies to explore investment opportunities that drive innovation and
advance life-changing therapeutics,” said Sara Jane Demy, founder and
CEO, Demy-Colton. “This year, we had more attendees than ever before,
including a record number of investors meeting with companies and
attending company presentations. This investor interest at both Biotech
Showcase and Digital Medicine & Medtech Showcase is what has attracted
the most exciting and cutting-edge companies year after year. Taken
together, this speaks to the impressive growth and high value that this
conference, and the surrounding week of activities, holds for the
biotech industry.”

“Now in our eleventh year, we are pleased that Biotech Showcase
continues to see record numbers of attendees with a strong showing from
both public and private presenting companies and more than 1,000
registered investors,” said Anna Chrisman, Group Managing Director, EBD
Group. “The announcements and discussions heard in the hallways,
partnering rooms, and presentation stages throughout the conference
provides key insights into the life science community and highlights the
trends that will shape the industry in the coming year.”

Some of the world’s leading biotech and pharmaceutical investors joined
CEOs, executives, and industry advisors in multiple panels, plenary
sessions, and workshops covering a wide variety of timely trends and
issues facing the industry. Reexamination of Alzheimer’s disease,
discussions on the state of industry financing, exploration of the RNA
therapeutic landscape, the outlook on gene therapy, and progress in rare
and orphan diseases were just a few of the topics addressed this year.

“Biotech Showcase offers a unique opportunity for life science investors
to gather and learn about new technologies and the progress of an
amazing array of innovative companies. Each year, our face to face
interactions with promising biotechnology companies provides significant
value by helping to inform our investing decisions over the next few
years,” said Eric Aguiar, MD, partner at Aisling Capital. “The
programming and structure of the conference continues to be an important
resource for the biotech investment community.”

Panelists from Biotech Showcase, Digital Health & Medtech Showcase, and
China Showcase took the time to provide their expertise on several key
issues facing the industry. This year’s speakers included leaders from
Celgene, Novo Nordisk, Roche, NEA, Third Rock, Venrock, Raymond James,
Pappas Capital, Blackrock, Piper Jaffray, and many more. Major sponsors
of the conference included Syneos Health, AstraZeneca, Covington, Hogan
Lovells, Johnson & Johnson Innovation, ClearView Healthcare Partners,
and Lonza.

The next Biotech Showcase will be held January 13-15, 2020 in San
Francisco. For more information go to BiotechShowcase.com.

About Demy-Colton

Since 2008, Demy-Colton has been at the forefront of building networks
between leaders from innovative biotech companies and industry
stakeholders to examine and address biotech opportunities and challenges
and deliver on the promise of transformational science.

We do this through facilitating networking and biotech community
development on an international scale. Our investor conferences and CEO
Summits expand communities that transcend geographical boundaries
establishing ongoing, high-value relationships that contributes greatly
to the evolution of the biopharmaceutical ecosystems we cultivate.

We set a unique stage where biotech leaders, investors, and stakeholders
can connect to realize significant opportunities for investment,
learning, and growth. Our events spur introductions and thoughtful
conversations. In turn, inspiration, ideas, and opportunities for
investment flow. Demy-Colton’s expanding portfolio of conferences
include:

• Biotech
  Showcase™ – a unique forum in San Francisco for presenting to
  investors and business development executives
• Digital
  Medicine & Medtech Showcase™ – A meeting, coinciding with
  Biotech Showcase, where key opinion leaders, investors and CEOs in the
  digital medicine and medtech spaces examine the latest industry
  advances and trends.
• China
  Showcase A one-day meeting, coinciding with Biotech Showcase, that
  highlights cross-border biotech investment and collaboration
  opportunities between China and the U.S.
• Biotech
  CEO Summit™ – An invitation-only, thought-provoking meeting for
  biotech industry leaders united by the common goal of driving
  responsible growth and innovation
• Biotech
  CEO Summit Europe™ – An invitation-only, one-of-a-kind event
  dedicated to helping the leadership of newly public and late stage
  private biotech companies navigate the constantly evolving biotech
  landscape

About EBD Group

EBD Group's overriding mission is to help collaborations get started
across the life science value chain. Our range of partnering conferences
has grown to become the largest and most productive conference platform
in the industry. Each one of our seven landmark events held in key life
science markets around the world is powered by our state-of-the-art
partnering software, partneringONE®,
that enables delegates to efficiently identify and engage with new
opportunities via one-to-one meetings.

Today our events (BIO-Europe®, BIO-Europe Spring®, BioPharm America™,
Biotech Showcase™, China Showcase, Digital Medicine & Medtech Showcase,
ChinaBio® Partnering Forum, Cell & Gene Connect, and BioEquity Europe)
annually attract more than 12,000 senior life science executives who
engage in over 48,000 one-to-one partnering meetings. These vital
one-to-one engagements are the wellspring of deals that drive innovation
in our industry.

Tune into EBD Group’s Partnering
Insight for timely coverage of news that influences the business
strategies of the life science industry. EBD Group is an Informa
company. For more information please visit www.ebdgroup.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20190122005171/en/